Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 4/20 | 0.62 |
| ▸ | LCK | P06239 | 2/20 | 0.62 |
| ▸ | SRC | P12931 | 2/20 | 0.62 |
| ▸ | JAK2 | O60674 | 8/20 | 0.52 |
| ▸ | JAK3 | P52333 | 8/20 | 0.52 |
| ▸ | JAK1 | P23458 | 4/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.47 |
| ▸ | PRKDC | P78527 | 2/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 4/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19732668 | 0.97 | RET (0.62) | RETLCKSRCJAK2JAK3 | |
| SCHEMBL19732764 | 0.95 | RET (0.61) | RETLCKSRCJAK2JAK3 | |
| SCHEMBL25678106 | 0.79 | JAK2 (0.53) | RETLCKSRCJAK2JAK3 | |
| SCHEMBL19732705 | 0.78 | RET (0.61) | RET | |
| SCHEMBL19732807 | 0.78 | RET (1.00) | RETLCKSRC | |
| SCHEMBL19732762 | 0.78 | RET (1.00) | RETLCKSRC | |
| SCHEMBL19303914 | 0.75 | RET (0.64) | RET | |
| SCHEMBL19732713 | 0.75 | RET (0.60) | RETLCKSRCPIK3CDBTK | |
| SCHEMBL25678092 | 0.75 | SRC (0.52) | RETLCKSRCJAK2JAK3 | |
| SCHEMBL19732735 | 0.75 | RET (1.00) | RETLCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236096-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-02-01 | — | — | US | disclosed |
| EP-3260454-B1 | CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-11014930-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-05-25 | — | — | US | disclosed |
| US-10981920-B2 | — | — | 2021-04-20 | — | — | US | disclosed |
| US-10787457-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-09-29 | — | — | US | disclosed |
| US-20200270260-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-08-27 | — | — | US | disclosed |
| US-20200270261-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-08-27 | — | — | US | disclosed |
| CN-108026101-B | Fused pyrimidine compound or salt thereof | 大鹏药品工业株式会社 | 2020-06-26 | — | — | CN | disclosed |
| US-20190092776-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-03-28 | — | — | US | disclosed |
| US-10233189-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-03-19 | — | — | US | disclosed |
| US-10179788-B2 | — | — | 2019-01-15 | — | — | US | disclosed |
| US-20180009817-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-01-11 | — | — | US | disclosed |
| EP-3260454-A1 | CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2017-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236096-B2 | Fused pyrimidine compound or salt thereof | RET, RB1, MECP2 | RET 1/4885LCK 580/4885SRC 153/4885 |
| US-10179788-B2 | — | RET, GFRA1, GFRA2 | RET 1/4885LCK 879/4885SRC 146/4885 |
| US-10233189-B2 | Fused pyrimidine compound or salt thereof | RET, RB1, MECP2 | RET 1/4885LCK 580/4885SRC 153/4885 |
| US-10787457-B2 | Fused pyrimidine compound or salt thereof | RET, RB1, MECP2 | RET 1/4885LCK 580/4885SRC 153/4885 |
| US-20180009817-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, RB1, MECP2 | RET 1/4885LCK 580/4885SRC 153/4885 |
| US-11014930-B2 | Fused pyrimidine compound or salt thereof | RET, RB1, MECP2 | RET 1/4885LCK 580/4885SRC 153/4885 |
| US-20200270260-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, RB1, MECP2 | RET 1/4885LCK 580/4885SRC 153/4885 |
| US-10981920-B2 | — | RET, GFRA1, GFRA2 | RET 1/4885LCK 879/4885SRC 146/4885 |
| US-20200270261-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, RB1, MECP2 | RET 1/4885LCK 580/4885SRC 153/4885 |
| US-20190092776-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, RB1, MECP2 | RET 1/4885LCK 580/4885SRC 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.